(19)
(11) EP 2 940 044 B8

(12) CORRECTED EUROPEAN PATENT SPECIFICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 B1)

(48) Corrigendum issued on:
18.01.2017 Bulletin 2017/03

(45) Mention of the grant of the patent:
16.11.2016 Bulletin 2016/46

(21) Application number: 15165133.8

(22) Date of filing: 05.06.2002
(51) International Patent Classification (IPC): 
A61K 39/395(2006.01)
A61P 19/02(2006.01)
 A61K 31/519(2006.01)

(54)

ANTI-TNF ALPHA ANTIBODIES FOR USE IN THERAPY

ANTI-TNF-ALPHA-ANTIKÖRPERN ZUR VERWENDUNG IN THERAPIE

ANTICORPS ANTI-TNF ALPHA POUR L'UTILISATION DANS LA THERAPIE

(84) Designated Contracting States:
AT BE CH CY DE DK ES FI FR GR IE IT LI LU MC NL PT SE TR
Designated Extension States:
AL LT LV MK RO SI

(30) Priority: 08.06.2001 US 296961 P

(43) Date of publication of application:
04.11.2015 Bulletin 2015/45

(60) Divisional application:
16198524.7

(62) Application number of the earlier application in accordance with Art. 76 EPC:
10182554.5 / 2359855
02741849.0 / 1406656

(73) Proprietor: AbbVie Biotechnology Ltd
HM 11 Hamilton (BM)

(72) Inventors:
  • Kempeni, Joachim
    67433 Neustadt (DE)
  • Weiss, Roberta
    Wynnewood, PA 19096 (US)
  • Fischkoff, Steven A.
    Short Hills, NJ 07078 (US)

(74) Representative: Adams, Harvey Vaughan John et al
Mathys & Squire LLP
The Shard 32 London Bridge Street London SE1 9SG
The Shard 32 London Bridge Street London SE1 9SG (GB)


(56) References cited: : 
   
  • RAU ROLF ET AL: "Long-term efficacy and tolerability of multiple I.V. doses of the fully human anti-TNF-antibody D2E7 in patients with rheumatoid arthritis", ARTHRITIS AND RHEUMATISM, vol. 41, no. 9 SUPPL., September 1998 (1998-09), page S55, XP002742018, & 62ND NATIONAL SCIENTIFIC MEETING OF THE AMERICAN COLLEGE OF RHEUMATOLOGY AND THE 33RD NATIONAL SCIEN; SAN DIEGO, CALIFORNIA, USA; NOVEMBER 8-12, 1998 ISSN: 0004-3591
  • R. RAU ET AL: "Effective Combination Of The Fully Human Anti-TNF Antibody D2E7 And methotrexate In Active Rheumatoid Arthritis", ANNALS OF THE RHEUMATIC DISEASES, vol. 58, no. (suppl.), ABST.907, 6 June 1999 (1999-06-06), page 217, XP002742019,
  • R. RAU ET AL: "Kombinationstherapie mit dem humanen Anti-TNF-Antikörper D2E7 und Methotrexat bei aktiver chronischer Polyarthritis", REGIONALTAGUNG DER DEUTSCHEN GESELLSCHAFT FÜR RHEUMATOLOGIE, vol. 58, no. Supp.1, ABST.F20, 16 September 1999 (1999-09-16), page I/35, XP002742020,
  • RAU R ET AL: "ERFAHRUNGEN MIT D2E7//EXPERIENCES WITH D2E7", AKTUELLE RHEUMATOLOGIE, THIEME MED. PUBL., NEW YORK, NY, US, vol. 25, no. 3, 1 January 2000 (2000-01-01), pages 83-88, XP008061373, ISSN: 0341-051X
  • VAN DE PUTTE LEO B A ET AL: "A single dose placebo controlled phase I study of the fully human anti-TNF antibody D2E7 in patients with rheumatoid arthritis", ARTHRITIS AND RHEUMATISM, vol. 41, no. 9 SUPPL., September 1998 (1998-09), page S57, XP002742021, & 62ND NATIONAL SCIENTIFIC MEETING OF THE AMERICAN COLLEGE OF RHEUMATOLOGY AND THE 33RD NATIONAL SCIEN; SAN DIEGO, CALIFORNIA, USA; NOVEMBER 8-12, 1998 ISSN: 0004-3591
  • VAN DE PUTTE L B A ET AL: "Efficacy of the fully human anti-TNF antibody D2E7 in rheumatoid arthritis", ARTHRITIS AND RHEUMATISM, vol. 42, no. 9 SUPPL., September 1999 (1999-09), page S400, XP002742022, & 63RD ANNUAL SCIENTIFIC MEETING OF THE AMERICAN COLLEGE OF RHEUMATOLOGY AND THE 34TH ANNUAL SCIENTIFI; BOSTON, MASSACHUSETTS, USA; NOVEMBER 13-17, 1999 ISSN: 0004-3591
  • VAN DE PUTTE ET AL: "Eine placebo-kontrollierte Phase-1-Studie des humanen Anti-TNF Antikörpers D2E7 bei Patienten mit aktiver chronischer Polyarthritis", ZEITSCHRIFT FÜR RHEUMATOLOGIEZEITSCHRIFT FÜR RHEUMATOLOGIE, vol. 58, no. suppl, ABST.F19, 1999, page I/34, XP002742023,
  • VAN DE PUTTE ET AL: "Six Month Efficacy Of The Fully Human Anti-TNF Antibody D2E7 In Rheumatoid Arthritis", ANNALS OF THE RHEUMATIC DISEASES, vol. 59, no. Suppl.1, OP.056, 2000, XP002742024,
  • VAN DE PUTTE ET AL: "One Year Efficacy Results Of The Fully Human Anti-TNF Antibody D2E7 In Rheumatoid Arthritis", ARTHRITIS & RHEUMATOLOGY, vol. 43, AB.1218, 2000, page S269, XP002742042,
  • SCHATTENKIRCHNER MANFRED ET AL: "Efficacy and tolerability of weekly subcutaneous injections of the fully human anti-TNF-antibody D2E7 in patients with rheumatoid arthritis: Results of a phase I study", ARTHRITIS AND RHEUMATISM, vol. 41, no. 9 SUPPL., September 1998 (1998-09), page S57, XP002742025, & 62ND NATIONAL SCIENTIFIC MEETING OF THE AMERICAN COLLEGE OF RHEUMATOLOGY AND THE 33RD NATIONAL SCIEN; SAN DIEGO, CALIFORNIA, USA; NOVEMBER 8-12, 1998 ISSN: 0004-3591
  • SCHATTENKIRCHNER ET AL: "Phase-1-Studie zur Wirksamkeit und Verträglichkeit wöchentlicher subcutaner Injektionen des humanen Anti-TNF Antikörpers D2E7 bei cP", REGIONALTAGUNG DER DEUTSCHEN GESELLSCHAFT FÜR RHEUMATOLOGIE, vol. 58, no. Suppl.1, ABST.P14, 16 September 1999 (1999-09-16), XP002742026,
  • SCHATTENKIRCHNER ET AL: "Long-Term Use Of The Fully HUman Anti-TNF Antibody D2E7 In Combination With Methotrexate In Active Rheumatoid Arthritis", ARTHRITIS & RHEUMATISM, vol. 43, no. S9, AB.968, September 2000 (2000-09), XP002742027,
  • KEMPENI JOACHIM ET AL: "Preliminary results of early clinical trials with the fully human anti-TNFalpha monoclonal antibody D2E7", ANNALS OF THE RHEUMATIC DISEASES, vol. 58, no. SUPPL. 1, December 1999 (1999-12), pages I70-I72, XP002742028, ISSN: 0003-4967
  • KEMPENI JOACHIM ET AL: "Update on D2E7: A fully human anti-tumour necrosis factor alpha monoclonal antibody", ANNALS OF THE RHEUMATIC DISEASES, vol. 59, no. Supplement 1, November 2000 (2000-11), pages i44-i45, XP002742029, ISSN: 0003-4967
  • WEISMAN ET AL: "A Dose Escalation Study Designed To Demonstrate The Safety, Tolerability And Efficacy Of The Fully Human Anti-TNF Antibody, D2E7, Given In Combination With Methotrexate (MTX) In Patients With Active RA", ARTHRITIS & RHEUMATISM, vol. 43, no. S9, AB.1948, September 2000 (2000-09), page S391, XP002742030,
  • SIMIANER ET AL: "One Year Treatment Results Of The Fully Human Anti-TNF Antibody D2E7 In Combination With Methotrexate In Active Rheumatoid Arthritis", ANNALS OF RHEUMATIC DISEASE, vol. 59, no. Suppl.1, POS-370, 2000, XP002742031,
  • RAU R: "Adalimumab (a fully human anti-tumour necrosis factor alpha monoclonal antibody) in the treatment of active rheumatoid arthritis: The initial results of five trials", ANNALS OF THE RHEUMATIC DISEASES, vol. 61, no. Supplement 2, November 2002 (2002-11), pages ii70-ii73, XP002742032, ISSN: 0003-4967
  • VAN DE PUTTE ET AL: "Efficacy and Safety of Adalimumab (D2E7), The First Fully Human Anti-TNF Monoclonal Antibody, In Patients With Rheumatoid Arthritis Who Failed Previous DMARD Therapy: 6-Month Results From A Phase IIII Study", , FRI0027, 2002, XP002742033, Retrieved from the Internet: URL:http://www.abstracts2view.com/eular/vi ew.php?nu=EULAR2L1_2002FRI0027 [retrieved on 2015-07-09]
  • VAN DE PUTTE L B A ET AL: "Efficacy and safety of the fully human anti-tumour necrosis factor alpha monoclonal antibody adalimumab (D2E7) in DMARD refractory patients with rheumatoid arthritis: A 12 week, phase II study.", ANNALS OF THE RHEUMATIC DISEASES, vol. 62, no. 12, December 2003 (2003-12), pages 1168-1177, XP002742034, ISSN: 0003-4967
  • VAN DE PUTTE B A ET AL: "Efficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failed", ANNALS OF THE RHEUMATIC DISEASES, vol. 63, no. 5, 1 May 2004 (2004-05-01), pages 508-516, XP002742035, ISSN: 0003-4967
  • KEYSTONE ET AL: "The ARMADA-Trial: A Double-Blind Placebo Controlled Trial Of The Fully Human Anti-TNF Monoclonal Antibody Adalimumab (D2E7) In Patients With Active RA On Methotrexate (MTX)", ARTHRITIS & RHEUMATISM, vol. 44, no. (suppl.), AB.965, 10 November 2001 (2001-11-10), XP002742036,
  • Keystone et al: "OP0086 THE FULLY HUMAN ANTI-TNF MONOCLONAL ANTIBODY, ADALIMUMAB (D2E7), DOSE RANGING STUDY: THE 24-WEEK CLINICAL RESULTS IN PATIENTS WITH ACTIVE RA ON METHOTREXATE THERAPY (THE ARMADA TRIAL)", , 15 June 2001 (2001-06-15), XP002742037, Retrieved from the Internet: URL:http://abstract.mci-group.com/cgi-bin/ mc/printabs.pl?APP=eular2001B-abstract&TEM PLATE=&keyf=1139&showHide=show [retrieved on 2015-07-09]
  • SORBERA L A ET AL: "Adalimumab. Antiarthritic treatment of IBD", DRUGS OF THE FUTURE, vol. 26, no. 7, July 2001 (2001-07), pages 639-646, XP002742038, ISSN: 0377-8282
  • WEINBLATT MICHAEL E ET AL: "Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial.", ARTHRITIS AND RHEUMATISM JAN 2003, vol. 48, no. 1, January 2003 (2003-01), pages 35-45, XP002742039, ISSN: 0004-3591
  • BREEDVELD FERDINAND C ET AL: "The PREMIER study: A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment.", ARTHRITIS AND RHEUMATISM JAN 2006, vol. 54, no. 1, January 2006 (2006-01), pages 26-37, XP002742040, ISSN: 0004-3591
  • Burmester et al: "EFFICACY, PHARMACOKINETICS, AND SAFETY OF DIFFERENT DOSES OF METHOTREXATE IN COMBINATION WITH ADALIMUMAB: RESULTS FROM THE CONCERTO TRIAL", Ann Rheum Dis 2013;72(Suppl3):72 , 2013, XP002742041, Retrieved from the Internet: URL:http://www.abstracts2view.com/eular/vi ew.php?nu=EULAR13L_OP0067 [retrieved on 2015-07-09]
 
Remarks:
The file contains technical information submitted after the application was filed and not included in this specification
 
Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).